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A 50-year-old male with chronic lymphocytic leukemia (CLL) was treated with fludarabine, cyclophosphamide and
rituximab, which produced a complete remission. Eight months after the last dose of rituximab he had visual
disturbance, diminished muscular strength in the right arm and vesicular-papular lesions in the left ophthalmic
branch region of the V cranial nerve. These were initially interpreted as herpes virus encephalopathy (HVE), but
brain magnetic resonance imaging (MRI) showed evidence of demyelination consistent with progressive multifocal
leukoencephalopathy (PML). Cerebrospinal fluid (CSF) analysis was negative for varicella zoster virus (VZV) and John
Cunningham virus (JCV) DNA. The clinical suggestion of PML prompted us to perform a brain biopsy and to start
treatment with mefloquine. In the brain biopsy, histopathological features of demyelination were described and the
polymerase chain reaction (PCR) identified JCV, confirming the diagnosis of PML. Treatment with mefloquine
(250 mg/week) and dexamethasone (4 mg/day) was started and maintained for 6 months. A year later there was an
almost complete resolution of the MRI lesions and the patient achieved a stable clinical state with persisting motor
impairment and severe epilepsy. The patient is alive 38 months after diagnosis of PML, which is the longest known
survival to date.
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Progressive multifocal leukoencephalopathy (PML) is a
rare demyelinating condition of the central nervous sys-
tem (CNS) that is frequently fatal. It is caused by reac-
tivation of latent John Cunningham virus (JCV) in the
context of immune system suppression, particularly in
patients infected with human immunodeficiency virus
(HIV) and in transplantation recipients, although it
was first described in patients with chronic lymphocytic
leukemia (CLL) and Hodgkin lymphoma [1,2]. Previous* Correspondence: jfgarcia@mdanderson.es
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tems are postulated risk factors.
The increasing number of PML cases recently diag-
nosed under monoclonal antibody therapy (rituximab,
alemtuzumab, brentuximab and natalizumab) highlights
the role of the immune system suppression in the patho-
genesis of PML [3-6].
Rituximab is a CD20-specific monoclonal antibody
that is effective in treating CLL. Rituximab therapy has
been associated with reactivation of viral infections
such as hepatitis B, cytomegalovirus, herpes simplex virus
(HSV), varicella zoster virus (VZV), West Nile virus and
JCV [3].
The pathophysiology of rituximab-associated PML is
unclear; some findings suggest that hematopoietic pro-
genitor cells may be a site of viral latency. Hematopoietic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ing chemotherapy may have been infected with latent JCV
and may have facilitated the hematogenous spread of JCV
into the central nervous system (CNS) [3].
The outcome of patients with PML is mostly unfavor-
able, leading to death in 90% with median survival of
only two months [3]. Historically, treatment of PML has
rarely been successful in the absence of immune system
reconstitution. To date there are no reports in the litera-
ture of patients diagnosed with PML and survival be-
yond 25 months, although it is possible that longer-term
survivors have not been reported.Case presentation
A 50-year-old Caucasian male patient presented with
visual disturbance and diminished muscular strength in
the right arm in August 2011.
He had a previous medical history of CLL in 2007 and
had a stable clinical condition for the following three
years, when increasing lymphocytosis, anemia, thrombo-
cytopenia and splenomegaly occurred, indicating CLL in
progression; he was then treated with six cycles of flu-
darabine, cyclophosphamide and rituximab, achieving
complete remission (CR) by the end of the treatment in
December 2010.
A neurological examination revealed subconjunctival
erythema in the left eye and vesicular-papular lesions in
the region of the left ophthalmic branch of the V cranial
nerve, dysarthria and paresis of the right arm. He had no
meningeal signs and no fever. There were no other me-
dically relevant personal or family conditions.
The presence of the cutaneous lesions accompanying
the neurological symptoms resulted in the condition be-
ing interpreted as herpes virus encephalopathy (HVE).
Other entities such as vasculitis, lymphomatous meningiosisFigure 1 Fluid-attenuated inversion recovery (FLAIR) images in the af
involving the parietal and occipital lobules and the internal capsule. B: Incr
after diagnosis. C: Complete resolution of the lesion, one year after diagnoby the underlying CLL or stroke were ruled out by clinical
and routine studies.
Treatment with intravenous acyclovir was initiated,
which produced an improvement in the skin lesions but
progressive deterioration of the neurological status of
the patient.
Blood count measurements showed a hemoglobin level
of 139 g/L, a total white cell count of 3.5×109/L and a
platelet count 98×109/L. All biochemical parameters
were normal.
Flow cytometry of the peripheral blood lymphocytes
revealed a non-clonal cell population; CD4+ and CD8+
counts were 222 cells/μL (normal limits, 400–1300
cells/μL) and 405 cells/μL (normal limits, 200–700
cells/μL), respectively.
Serology showed the following results: negative for
hepatitis B, hepatitis C, HIV and toxoplasmosis IgG and
IgM. HSV type I IgG positive and IgM negative.
Cerebrospinal fluid (CSF) analysis indicated a normal
cell count, and normal protein and glucose levels, with
no evidence of neoplastic cells. Polymerase chain reac-
tion (PCR) analysis of the CSF was negative for JCV,
HSV RNA, cytomegalovirus RNA, herpes virus Type 6
(HVT6) DNA and VZV DNA.
Magnetic resonance imaging (MRI) of the brain showed
a bilateral hyperintensity (Figure 1A) in the white mat-
ter involving the parietal and occipital lobules and the
internal capsule; there was no mass effect, edema, he-
morrhagic or ischemic lesions. Although the JCV was not
detected in the CSF, the findings were consistent with de-
myelination and suggestive of PML and while waiting for
the PCR results, empirical treatment was initiated with
oral mefloquine and a brain biopsy was performed.
Histological examination of the sample revealed infiltra-
tion of the brain tissue by foamy macrophages and mature
lymphocytes with perivascular clustering (Figure 2A).fected regions. A: bilateral hyperintensity in the white matter
ement in the extension and intensity of the parietal lesion, one month
sis.
Figure 2 Histological examination. A: Infiltration of the brain tissue by foamy macrophages and mature lymphocytes with perivascular
clustering. B: Immunohistochemical staining for neurofilaments revealed a loss of myelin. Compare affected tissue at the bottom with normal
brain tissue at the upper corner of the picture. C: Reactive astrocytes with polymorphic nuclei and prominent nucleoli.
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vealed a loss of myelin (Figure 2B). Within the lesion,
astrocytes were reactive and exhibited polymorphic
nuclei and prominent nucleoli (Figure 2C). After the
presumptive diagnosis of PML, it was decided to con-
tinue treatment with mefloquine (250 mg/week) and
dexamethasone (4 mg/day) for 6 months. Finally the
PCR study of the biopsy specimen demonstrated the
presence of JCV (5874 copies of JCV DNA /mL tissue
suspension).
In the subsequent weeks, the neurological condition of
the patient continued to deteriorate, with continuous
epileptic fits, motor impairment with left hemiparesia,
along with an increment in the extension and intensity
of the parietal lesion, as revealed by a further MRI one
month after diagnosis (Figure 1B). Thereafter, neurolo-
gical condition and the MRI findings progressively im-
proved and a year after diagnosis the patient achieved an
almost complete resolution of the lesion as indicated by
MRI, despite persisting residual motor impairment and
epilepsy (Figure 1C). The patient is alive 38 months after
the diagnosis. CLL continues to be in CR.Discussion
The significant aspects of this case are the difficulty of
reaching the correct diagnosis and the long-term sur-
vival of the patient after the diagnosis of PML, which is
the longest reported to date.
Risk factors for developing PML in HIV-infected people
include low CD4+ lymphocyte count, whereas those in
HIV-negative people remains a matter of debate [3]. In
our patient, PML was associated with immunological dys-
function in relation to the baseline hematological disease,
[7] receiving previous treatments (purine analogs, alkylat-
ing agents) [3] and/or monoclonal antibody therapy with
rituximab [3,5]. All these elements, individually or in com-
bination, led to an immunosuppression that has persistedin the patient to the present day, maintaining a low CD4+
count (339 cells/μL) 3 years after the treatment.
Establishing a diagnosis of PML requires the identifi-
cation of JCV DNA in the CSF in conjunction with the
characteristic neuroimaging findings or the demonstra-
tion of the typical histopathological triad (demyelination,
bizarre astrocytes, and enlarged oligodendroglial nuclei),
and coupled with the techniques to show the presence
of JCV [8]. In the present case, the failure of PCR to
demonstrate the JCV in CSF prompted us to perform a
brain biopsy to establish a diagnosis, once the initial
possibility of HVE became inconsistent and PML was
the most likely possibility.
Several agents have been used to treat PML, although
these treatments have been based on limited data, and
none has proven consistently effective against JCV. In
vitro studies of various compounds with anti-JCV activ-
ities showed that only mefloquine, an antimalarial agent,
has sufficiently high penetration into the CNS. Addi-
tional experiments demonstrated that mefloquine in-
hibits the viral infection rates of three JCV isolates: JCV
(Mad1), JCV(Mad4), and JCV(M1/SVEDelta). This effect
is exerted in three cell types: transformed human glial
(SVG-A) cells, primary human fetal glial cells, and pri-
mary human astrocytes. Mefloquine was also shown to
inhibit viral DNA replication [9] when quantitative PCR
was used to determine the number of viral copies in cul-
tured cells.
Steroid treatment is usually given in HIV-negative
PML-immune reconstitution inflammatory syndrome
(IRIS) patients in an effort to dampen the inflammatory
response. Although some published cases showed pos-
sible benefits, [10] the use of steroids to treat PML
remains controversial because these medications are im-
munosuppressants and may contribute to increase HIV
replication in HIV-positive patients, or disrupt treat-
ment plans in HIV-negative patients with cancer or
autoimmune diseases.
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malignancy is less than 3 months [3,7]. Carson reported
an overall case-fatality rate of 90%: 100% among PML
cases diagnosed within 3 months of the last rituximab
dose versus 84% among PML cases diagnosed more than
3 months after the last rituximab dose [3].
In this large series of 57 cases of HIV-negative pa-
tients treated with rituximab only 5 patients survived: 2
received no therapy, 1 received cytarabine, another mir-
tazapine, and the last received cidofovir, donor lympho-
cyte infusions, cytarabine and risperidone. None of these
patients received the mefloquine and dexamethasone
combination.
Clifford et al., in a clinical research, could not demon-
strate any concluding results about the benefits of mef-
loquine in the treatment of PML. The small number of
evaluable patients in this trial reflects the logistical and
technical challenges inherent in PML clinical studies
and larger investigations are needed to reach definitive
conclusions [11].
The present case is one of the few examples of long-
term survival of this condition, although it is not possible
to determine whether the treatment with mefloquine in-
fluenced this outcome.
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